No significant correlations between the Th2/Th1 ratio and other clinico-biologic characteristics of CLL patients were found, possibly due to the low number of patients belonging to specific biologic subgroups (Rai stage 0-I-II [n=21] vs. III-IV [n= 9]; FISH del13q/+12/normal [n=23] vs del17p/del11q [n=7]; TP53 wild-type [n=25] vs mutated [n=5]; NOTCH1 wild-type [n=20] vs mutated [n=5]; SF3B1 wild-type [n=23] vs mutated [n=2]; BIRC3 wild-type [n=21] vs mutated [n=4]). This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.